Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Return on Invested Capital (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Return on Invested Capital for 12 consecutive years, with 0.01% as the latest value for Q4 2025.

  • Quarterly Return on Invested Capital fell 127.0% to 0.01% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.01% through Dec 2025, down 127.0% year-over-year, with the annual reading at 0.01% for FY2025, 119.0% down from the prior year.
  • Return on Invested Capital for Q4 2025 was 0.01% at Theravance Biopharma, up from 0.12% in the prior quarter.
  • The five-year high for Return on Invested Capital was 1.26% in Q4 2024, with the low at 2.0% in Q1 2025.
  • Average Return on Invested Capital over 5 years is 0.01%, with a median of 0.16% recorded in 2023.
  • The sharpest move saw Return on Invested Capital plummeted -289bps in 2022, then surged 173bps in 2023.
  • Over 5 years, Return on Invested Capital stood at 0.81% in 2021, then plummeted by -124bps to 0.2% in 2022, then tumbled by -37bps to 0.27% in 2023, then skyrocketed by 562bps to 1.26% in 2024, then crashed by -101bps to 0.01% in 2025.
  • According to Business Quant data, Return on Invested Capital over the past three periods came in at 0.01%, 0.12%, and 0.13% for Q4 2025, Q3 2025, and Q2 2025 respectively.